Cryofocus Medtech (Shanghai) Co., Ltd.

SEHK:6922 Stock Report

Market Cap: HK$1.9b

Cryofocus Medtech (Shanghai) Management

Management criteria checks 2/4

Cryofocus Medtech (Shanghai)'s CEO is Jun Zhu, appointed in Oct 2020, has a tenure of 4.25 years. total yearly compensation is CN¥12.19M, comprised of 20% salary and 80% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth HK$11.84M. The average tenure of the management team and the board of directors is 4.3 years and 3.3 years respectively.

Key information

Jun Zhu

Chief executive officer

CN¥12.2m

Total compensation

CEO salary percentage20.0%
CEO tenure4.3yrs
CEO ownership0.6%
Management average tenure4.3yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Is Cryofocus Medtech (Shanghai) (HKG:6922) Using Too Much Debt?

Sep 02
Is Cryofocus Medtech (Shanghai) (HKG:6922) Using Too Much Debt?

We're Not Very Worried About Cryofocus Medtech (Shanghai)'s (HKG:6922) Cash Burn Rate

Jan 10
We're Not Very Worried About Cryofocus Medtech (Shanghai)'s (HKG:6922) Cash Burn Rate

Cryofocus Medtech (Shanghai) (HKG:6922) Is In A Good Position To Deliver On Growth Plans

Oct 03
Cryofocus Medtech (Shanghai) (HKG:6922) Is In A Good Position To Deliver On Growth Plans

Companies Like Cryofocus Medtech (Shanghai) (HKG:6922) Are In A Position To Invest In Growth

May 30
Companies Like Cryofocus Medtech (Shanghai) (HKG:6922) Are In A Position To Invest In Growth

CEO Compensation Analysis

How has Jun Zhu's remuneration changed compared to Cryofocus Medtech (Shanghai)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥106m

Mar 31 2024n/an/a

-CN¥102m

Dec 31 2023CN¥12mCN¥2m

-CN¥97m

Sep 30 2023n/an/a

-CN¥105m

Jun 30 2023n/an/a

-CN¥113m

Mar 31 2023n/an/a

-CN¥113m

Dec 31 2022CN¥12mCN¥2m

-CN¥112m

Dec 31 2021CN¥7mCN¥2m

-CN¥102m

Dec 31 2020CN¥850kCN¥836k

-CN¥137m

Compensation vs Market: Jun's total compensation ($USD1.67M) is above average for companies of similar size in the Hong Kong market ($USD351.66K).

Compensation vs Earnings: Jun's compensation has increased whilst the company is unprofitable.

CEO

Jun Zhu (49 yo)

4.3yrs

Tenure

CN¥12,194,000

Compensation

Mr. Jun Zhu serves as Consultant at Proxima Ventures, where he was previously an External Consultant. Mr. Zhu serves as General Manager at Cryofocus Medtech (Shanghai) Co., Ltd. since October 2020 and ser...

Leadership Team

NamePositionTenureCompensationOwnership
Kejian Li
Executive Chairman of the Board11.8yrsno data0.036%
HK$ 691.5k
Jun Zhu
GM & Executive Director4.3yrsCN¥12.19m0.62%
HK$ 11.8m
Wei Liu
CFO, Joint Company Secretary & Executive Director4.3yrsCN¥1.72mno data
Kuiwen Zhao
Technical Director and R&D Manager5.8yrsno datano data
Jihong Qu
Chief Medical Officer2.8yrsno datano data
Zhimin Chen
Executive Vice President of Ningbo SensCure8yrsno datano data
Wai Yan Leung
Joint Company Secretay3.1yrsno datano data
Yuepeng Diao
Deputy Vice President11.3yrsno datano data

4.3yrs

Average Tenure

41yo

Average Age

Experienced Management: 6922's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kejian Li
Executive Chairman of the Board11.8yrsno data0.036%
HK$ 691.5k
Jun Zhu
GM & Executive Director4yrsCN¥12.19m0.62%
HK$ 11.8m
Wei Liu
CFO, Joint Company Secretary & Executive Director1.6yrsCN¥1.72mno data
Hsien Tse Liang
Independent Non-Executive Director3.1yrsCN¥200.00kno data
Dayong Gao
Independent Non-Executive Director3.1yrsCN¥280.00kno data
Shiwen Lv
Non-Executive Director10.5yrsno data9.15%
HK$ 175.8m
Haorong Zhu
Supervisor4.6yrsno datano data
Zheng Qin
Independent Non-Executive Director3.1yrsCN¥200.00kno data
Chunsheng Zhao
Non-Executive Director3.6yrsno datano data
Henan Hu
Independent Non-Executive Director2.2yrsCN¥200.00kno data
Junkang Qiu
Supervisor6.2yrsno datano data
Jiawei Li
Chairperson of the Board of Supervisors1.7yrsno datano data

3.3yrs

Average Tenure

50yo

Average Age

Experienced Board: 6922's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 05:52
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cryofocus Medtech (Shanghai) Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullGuoyuan Securities (HK) Ltd
Wen DaiHuatai Research